Moreover, in some cases, combined inhibition of oncogenic signaling plus autophagy has been shown to be an effective strategy for the treatment of cancers driven by oncogenic KRAS or BRAF both in preclinical models and in clinical trials. The gene discussed is KRAS; the disease is cancer.